Cargando…

Aseptic meningitis after BNT-162b2 COVID-19 vaccination

The COVID-19 pandemic has had an unprecedented impact on healthcare systems globally, giving rise to significant morbidity and mortality. Vaccination has been widely regarded as the most important strategy to contain the pandemic. Whilst local side-effects of the BNT-162b2 (Pfizer-BioNTech) vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chan, Amanda CY., Tan, Benjamin YQ., Goh, Yihui, Tan, Shaun SY., Tambyah, Paul A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667462/ https://www.ncbi.nlm.nih.gov/pubmed/34927105 http://dx.doi.org/10.1016/j.bbih.2021.100406

Ejemplares similares

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Steroid-responsive aseptic meningitis after BNT162b2 SARS-CoV-2 vaccine
por: Reis Carneiro, D., et al.
Publicado: (2022)

Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19
por: Kang, Kyusik, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon
por: Moghnieh, Rima, et al.
Publicado: (2021)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Comments on “Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19”
por: Finsterer, Josef
Publicado: (2023)

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021)

Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis
por: Michos, Athanasios, et al.
Publicado: (2022)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
por: Zaqout, Ahmed, et al.
Publicado: (2021)

Kinetics of SARS-CoV-2 anti-S IgG after BNT162b2 vaccination
por: Grupel, Daniel, et al.
Publicado: (2021)

A case of reactivation of varicella–zoster virus after BNT162b2 vaccine second dose?
por: Santovito, Luca Spiro, et al.
Publicado: (2021)

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 among healthcare workers
por: Sansone, Emanuele, et al.
Publicado: (2021)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
por: Lim, Xin Rong, et al.
Publicado: (2021)

Oropharyngeal shedding of herpesviruses before and after BNT162b2 mRNA vaccination against COVID-19
por: Brosh-Nissimov, Tal, et al.
Publicado: (2021)

Negative effect of the second dose of the BNT162b2 vaccine in a significant percentage of individuals with previous COVID infection
por: Baos, Elvira, et al.
Publicado: (2022)

Second dose of the BNT162b2 mRNA vaccine: Value of timely administration but questionable necessity among the seropositive
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy
por: Jedicke, Nils, et al.
Publicado: (2021)

No significant influence of pre-vaccination antipyretic use on specific antibody response to a BNT162b2 vaccine booster against COVID-19
por: Tani, Naoki, et al.
Publicado: (2022)

Fulminant myocarditis and systemic hyperinflammation temporally associated with BNT162b2 mRNA COVID-19 vaccination in two patients
por: Abbate, Antonio, et al.
Publicado: (2021)

Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection
por: Bongiovanni, Marco, et al.
Publicado: (2021)

Humoral immune response to Comirnaty (BNT162b2) SARS-Cov2 mRNA vaccine in Thalassemia Major patients
por: Anastasi, Emanuela, et al.
Publicado: (2022)

One-year dynamics of antibody titers after three doses of SARS-CoV-2 BNT162b2 vaccine
por: Wand, Ori, et al.
Publicado: (2023)

Re: Comments on “Recurrent Aseptic Meningoencephalitis Following BNT162b2 Vaccination for COVID-19”: The Authors Respond
por: Kang, Kyusik, et al.
Publicado: (2023)

Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2022)

Immunological features that associate with the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2
por: Kageyama, Takahiro, et al.
Publicado: (2022)

First-generation BNT162b2 and AZD1222 vaccines protect from COVID-19 pneumonia during the Omicron variant emergence
por: Murillo-Zamora, E., et al.
Publicado: (2022)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients
por: Cuffel, Alexis, et al.
Publicado: (2022)

Safety and antibody response of recipients who unexpectedly received undiluted prime dose of BNT162b2 COVID-19 vaccine in Taiwan
por: Sheng, Wang-Huei, et al.
Publicado: (2023)

COVID-19 mRNA vaccine BNT162b2 induces autoantibodies against type I interferons in a healthy woman
por: Ning, Wangbin, et al.
Publicado: (2022)

Myocarditis/pericarditis following vaccination with BNT162b2, CoronaVac, and ChAdOx1 among adolescent and adult in Malaysia
por: Ab Rahman, Norazida, et al.
Publicado: (2023)

Immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in elderly people over 85 years of age in Greece: the GREVAXIMO study
por: Kontopoulou, Konstantina, et al.
Publicado: (2021)

The effect of the E484K mutation of SARS-CoV-2 on the neutralizing activity of antibodies from BNT162b2 vaccinated individuals
por: Uwamino, Yoshifumi, et al.
Publicado: (2022)

Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine
por: Raw, Rachael K., et al.
Publicado: (2022)

SARS-CoV-2 outbreak in a nursing home after vaccination with BNT162b2: A role for the quantification of circulating antibodies
por: Càmara, Jordi, et al.
Publicado: (2022)

Human enteroviruses in cerebrospinal fluid of children with suspected aseptic meningitis: A study in northern Iran
por: Sadeghi, Farzin, et al.
Publicado: (2017)

Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study
por: García-Grimshaw, Miguel, et al.
Publicado: (2021)

Vaccine-induced humoral response against SARS-CoV-2 dramatically declined but cellular immunity possibly remained at 6 months post BNT162b2 vaccination
por: Kato, Hideaki, et al.
Publicado: (2022)

Real-world effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection among adolescents (12 to 17-year-olds) in Malaysia
por: Husin, Masliyana, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_h78oloqiub54q62kgb79fvkon0